{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:42:33Z","timestamp":1792622553566,"version":"4.5.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Fibrotic skin diseases are rare, chronic, and often debilitating conditions characterized by excessive extracellular matrix deposition, leading to tissue scarring and functional impairment. Despite their severity, diseases\u2014such as lichen sclerosus et atrophicus (LSA), frontal fibrosing alopecia (FFA), radiation-induced skin fibrosis (RISF), eosinophilic fasciitis (EF), pansclerotic disabling morphea (PDM), and linear circumscript sclerodermia (LCS)\u2014lack approved therapies and are underrepresented in clinical research. This phase 2b multicenter basket trial proposes a novel approach to evaluate a common antifibrotic therapy across these diverse but pathophysiologically related conditions. The trial employs a two-stage Simon design to address the statistical challenges posed by small patient populations, allowing the inclusion of ultra-rare diseases while maintaining analytical rigor. LSA and FFA serve as primary study groups due to higher prevalence, while EF, RISF, PDM, and LCS are included as exploratory arms. The study aims to assess the efficacy, safety, and tolerability of the selected therapy, while also providing mechanistic insights into fibrosis through molecular analyses. The primary endpoint is a\u202f\u2265\u202f1-point improvement in the Investigator Global Assessment (IGA) at 24\u202fweeks. Secondary endpoints at 52\u202fweeks encompass quality of life (Dermatological Life Quality Index (DLQI), EuroQol Group Quality of Life Questionnaire (EuroQol five dimensions (EQ-5D))), symptom relief (itch and pain Numeric Rating Scale (NRS)), and disease-specific clinical scores. The trial excludes a placebo arm due to ethical considerations in progressive, untreated diseases but allows rescue therapies for disease progression. This design not only facilitates access to treatment for underserved populations but also leverages shared clinical and molecular features to enhance statistical power. By integrating disease-specific and global outcome measures, the study aims to generate robust evidence for repurposing existing therapies. If successful, this trial could serve as a model for future research in rare fibrotic diseases, accelerating drug development and improving patient outcomes.<\/jats:p>","DOI":"10.3389\/fmed.2025.1637040","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:13:18Z","timestamp":1758600798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 2b basket trial approach to treat multiple rare and fibrotic skin diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Sebastian","family":"Volc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schefzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Moinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Susok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n A.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manola","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ddg.15541","article-title":"Update vulval dermatology - diagnostics and therapy","volume":"23","author":"Bragelmann","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/bjd.21786","article-title":"Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study","volume":"187","author":"Cook","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00404-024-07519-w","article-title":"Patient satisfaction and sexual issues in vulvar lichen sclerosus treatment: a monocentric certified dysplasia unit survey analysis","volume":"310","author":"Meyer-Wilmes","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00431-025-06063-2","article-title":"Paediatric and adolescent vulvar lichen sclerosus: delay in diagnosis","volume":"184","author":"Crofts","year":"2025","journal-title":"Eur J Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/MOP.0000000000001370","article-title":"Vulvar skin disease in the pediatric population","volume":"36","author":"Griffith","year":"2024","journal-title":"Curr Opin Pediatr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","article-title":"The Il-4\/Il-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets","volume":"312","author":"Nguyen","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1165\/rcmb.2022-0301OC","article-title":"Molecular features and stages of pulmonary fibrosis driven by type 2 inflammation","volume":"69","author":"Mattoo","year":"2023","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1801130","DOI":"10.1183\/13993003.01130-2018","article-title":"Sar156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (Dri11772)","volume":"52","author":"Raghu","year":"2018","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1902442","DOI":"10.1183\/13993003.02442-2019","article-title":"Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Maher","year":"2021","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/09622802251316961","article-title":"How to add baskets to an ongoing basket trial with information borrowing","volume":"34","author":"Daniells","year":"2025","journal-title":"Stat Methods Med Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase ii clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2017.04.004","article-title":"Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis","volume":"16","author":"Vandevanter","year":"2017","journal-title":"J Cyst Fibros"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"102211","DOI":"10.1016\/j.coph.2022.102211","article-title":"Current advances in the treatment of systemic sclerosis","volume":"64","author":"Bukiri","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0147215","DOI":"10.1371\/journal.pone.0147215","article-title":"When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis","volume":"11","author":"Scannell","year":"2016","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12916-020-01808-2","article-title":"Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs","volume":"18","author":"Burnett","year":"2020","journal-title":"BMC Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1637040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:13:19Z","timestamp":1758600799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1637040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":16,"alternative-id":["10.3389\/fmed.2025.1637040"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1637040","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1637040"}}